Nirvana Life Sciences Inc.
NIRVF
$0.083
$0.0830.00%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -54.26% | -58.79% | -70.10% | -59.77% | -24.19% |
| Depreciation & Amortization | -- | -- | -- | -73.37% | -47.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.39% | -64.27% | -76.85% | -56.14% | -25.02% |
| Operating Income | 63.39% | 64.27% | 76.85% | 56.14% | 25.02% |
| Income Before Tax | 68.19% | 63.88% | 84.87% | 50.79% | 0.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.19% | 63.88% | 84.87% | 50.79% | 0.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -84.62% | -33.33% | -75.00% | -86.67% | 0.00% |
| Net Income | 68.05% | 63.87% | 84.89% | 50.70% | 0.17% |
| EBIT | 63.39% | 64.27% | 76.85% | 56.14% | 25.02% |
| EBITDA | 65.19% | 61.46% | 76.36% | 55.16% | 18.21% |
| EPS Basic | 68.06% | 63.81% | 86.80% | 65.31% | 29.41% |
| Normalized Basic EPS | 67.86% | 63.75% | 87.76% | 70.31% | 29.56% |
| EPS Diluted | 68.06% | 63.81% | 86.80% | 65.31% | 29.41% |
| Normalized Diluted EPS | 67.86% | 63.75% | 87.76% | 70.31% | 29.56% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 14.75% | 42.05% | 41.72% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 14.75% | 42.05% | 41.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |